Mortality trends in the era of antiretroviral therapy: evidence from the Network for Analysing Longitudinal Population based HIV/AIDS data on Africa (ALPHA). by Reniers, Georges et al.
Reniers, G; Slaymaker, E; Nakiyingi-Miiro, J; Nyamukapa, C; Crampin,
AC; Herbst, K; Urassa, M; Otieno, F; Gregson, S; Sewe, M; Michael,
D; Lutalo, T; Hosegood, V; Kasamba, I; Price, A; Nabukalu, D;
Mclean, E; Zaba, B; on behalf of the ALPHA Network (2014) Mortal-
ity trends in the era of antiretroviral therapy: evidence from the Net-
work for Analysing Longitudinal Population based HIV/AIDS data
on Africa (ALPHA). AIDS (London, England), 28 Suppl 4. S533-
S542. ISSN 0269-9370 DOI: 10.1097/QAD.0000000000000496
Downloaded from: http://researchonline.lshtm.ac.uk/2025492/
DOI: 10.1097/QAD.0000000000000496
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Mortality trends in the era of antiretroviral therapy:
evidence from the Network for Analysing
Longitudinal Population based HIV/AIDS data
on Africa (ALPHA)
Georges Reniersa, Emma Slaymakera, Jessica Nakiyingi-Miirob,
Constance Nyamukapac, Amelia Catharine Crampina,d, Kobus Herbste,
Mark Urassaf, Fred Otienog, Simon Gregsonc,h, Maquins Seweg,
Denna Michaelf, Tom Lutaloi, Victoria Hosegoode,j, Ivan Kasambab,
Alison Pricea,d, Dorean Nabukalui, Estelle Mcleana, Basia Zabaa,
on behalf of the ALPHA Network
Background: The rollout of antiretroviral therapy (ART) is one of the largest public
health interventions in Eastern and Southern Africa of recent years. Its impact is well
described in clinical cohort studies, but population-based evidence is rare.
Methods: We use data from seven demographic surveillance sites that also conduct
community-based HIV testing and collect information on the uptake of HIV services.
We present crude death rates of adults (aged 15–64) for the period 2000–2011 by sex,
HIV status, and treatment status. Parametric survival models are used to estimate age-
adjusted trends in the mortality rates of people living with HIV (PLHIV) before and after
the introduction of ART.
Results: The pooled ALPHA Network dataset contains 2.4 million person-years of
follow-up time, and 39114 deaths (6893 to PLHIV). The mortality rates of PLHIV have
been relatively static before the availability of ART. Mortality declined rapidly there-
after, with typical declines between 10 and 20% per annum. Compared with the pre-
ART era, the total decline in mortality rates of PLHIV exceeds 58% in all study sites with
available data, and amounts to 84% for women in Masaka (Uganda). Mortality declines
have been larger for women than for men; a result that is statistically significant in five
sites. Apart from the early phase of treatment scale up, when the mortality of PLHIV on
ART was often very high, mortality declines have been observed in PLHIV both on and
off ART.
Conclusion: The expansion of treatment has had a large and pervasive effect on adult
mortality. Mortality declines have been more pronounced for women, a factor that is often
attributed to women’s greater engagement with HIV services. Improvements in the timing
of ART initiation have contributed to mortality reductions in PLHIV on ART, but also
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Introduction
The expansion of HIV care and treatment services is one
of the largest public health interventions in sub-Saharan
Africa of recent times, but it is notoriously difficult to
evaluate its population-wide impact because many of the
countries that are hardest hit by the epidemic have poor
registration of vital events. Clinical cohort studies fill part
of the information gap, and suggest that the mortality
levels of patients who start treatment early and do not
default approaches that of HIV-negative individuals of the
same age [1–3]. Clinical studies have also shown,
however, that late presentation and patient attrition
continue to limit the efficacy of ART [3–5]. The true
magnitude of the mortality associated with these
phenomena is harder to estimate. Intensive patient
tracing studies have shed light on the mortality of
patients who are lost to follow-up [6], but estimating
mortality in HIV positives who never make contact with
the health system remains intractable with clinic-based
study designs.
This situation thus calls for a population-based assessment
of mortality trends, and in this contribution we use data
from seven demographic and HIV surveillance sites in six
eastern and southern African countries. Several of these
studies have previously reported on the impact of HIVon
adult mortality [7–12]. This study differs from earlier
analyses because the data range is extended to 2011, and
thus covers several years during which ARTwas locally
available. We also use individually-linked information on
HIV testing and treatment uptake, which allows us to
estimate the mortality trends of people living with HIV
(PLHIV), and disaggregate those estimates by their
treatment status.
Most of our estimates are presented for men and women
separately. Gender equity in the uptake of ART has been a
concern since the early days of the treatment scale up;
initially because of women’s elevated HIV prevalence and
concerns that men had privileged access to treatment
in places where it was offered under a patient copay
scheme [13,14]. Current programme statistics suggest
the opposite gender disparity: nationally representative
surveys from Africa consistently report higher female
HIV Testing and Counseling (HTC) coverage rates [15],
and a disproportionately large number of women are on
ART compared with estimated need in both sexes
[16,17]. Women are also less likely to enroll with
advanced disease, and tend to have lower attrition and
mortality rates following treatment initiation [17–21].
Methods
ALPHA Network study sites and data
Data for this study come from seven members of the
Network for Analysing Longitudinal Population-based
HIV/AIDS data on Africa (http://alpha.lshtm.ac.uk/),
located in six countries as shown in Fig. 1. ALPHA
Network study sites cover populations ranging from
20 000 to 200 000 in size. With the exception of the
Manicaland study (wherein the individuals consist of
residents in a set of eight noncontiguous areas chosen to
represent distinct socioeconomic zones), the surveillance
sites exhaustively cover the entire population of a
circumscribed area. Demographic information is col-
lected through regular censuses, generally conducted as
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Fig. 1. Location of the ALPHA Network sites contributing
data to this study. We use location names to refer to the study
sites. Other names are sometimes used for Kisesa (Magu
Demographic Surveillance System), Kisumu (Kenya Medical
Research Institute/Centers for Disease Control and Preven-
tion, KEMRI/CDC HDSS), Masaka (General Population
Cohort in the Kyamulibwa sub-district), and uMkhanyakude
(Africa Centre Demographic Information System, ACDIS).
interviews with a senior household member who acts as a
proxy respondent on behalf of the whole household.
Prepopulated lists of household members from the last
census round are used by the fieldworker to inquire about
the residency and survival status of all household residents.
In Karonga, village informants assist with the demo-
graphic surveillance [22]. The size of the study sites and
the intervals at which demographic surveillance is carried
out vary across sites and have a bearing on the range of
analyses possible with each site’s data and the precision of
the resulting estimates.
Along with the demographic surveillance, all ALPHA
members organize post-mortem interviews with relatives
of deceased residents (verbal autopsies) and repeated
population-based HIV serosurveys, either via home visits
or mobile HIV testing centers to which residents are
invited. HIV testing protocols and participation rates
have varied over time and between sites. Prior to the
availability of rapid HIV tests and treatment, residents
were often referred to a medical facility in the vicinity for
the return of their test results, or directed to a separate
testing and counseling service. In recent serosurveys, most
ALPHA Network studies give residents the opportunity
to receive standard HTC in the same visit that specimens
for a research test are collected. The serosurveys also use
individual interviews to collect behavioral data, including
information about utilization of HIV and AIDS care
services.
The demographic surveillance data used in this study
are continuously updated – the dataset used in this
analysis was assembled in September 2014, spans the
period 2000–2011, and thus covers several years before
and after the introduction of ART. Several study sites
started HIV surveys later than the demographic sur-
veillance, so their HIV status information is restricted to
a narrower time span. The date ranges used for overall
mortality estimates and mortality estimates by HIV
status are stipulated for each study site in the first
column of Table 1. Most ALPHA Network members
have published cohort profiles with detailed descrip-
tions of the population characteristics and fieldwork
procedures [22–25], and in some cases also methodo-
logical studies describing the HIV serosurveys, non-
response rates, and associated bias in HIV prevalence
estimates [26,27].
Our measure of exposure time for the risk of dying comes
from the residence episodes of men and women in the
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Table 1. Site-specific characteristics of the study populations, and HIVR/HIVS mortality rate ratios.
Study site, country Individuals, person-years and deaths by HIV status Mortality rates and RR
2000–2003 2009–2011
Dates, all-cause mortality
Dates, mortality by HIV
Average
HIV%a HIV status
Individuals
(ages 15–64)
Person-
years Deaths
Death rate
(per 1000)
HIVþ/HIV–
RR (95% CI)
Death rate
(per 1000)
HIVþ/HIV–
RR (95% CI)
Karonga, MAW 11.3 All 30 397 144 479 1486 14.6 ND 7.6 3.9
2003–2011 HIV 17 156 47 204 230 ND 5.3 (3.0–5.1)
2006–2011 HIVþ 1761 5320 149 ND 20.8
HIV unknownb 29 384 91 955 1107 ND 10.8
Kisesa, TAZ 5.9 All 45 540 171 619 1791 12.5 8.4 8.0 5.3
2000–2011 HIV– 18 192 82 108 697 9.1 (6.7–10.7) 7.0 (3.8–7.3)
2000–2011 HIVþ 1507 4750 275 76.9 36.9
HIV unknownb 40 018 84 761 819 12.3 7.4
Kisumu, KEN 24.6 All 229 177 901 590 17 289 25.6 ND 15.0 2.6
2003–2011 HIV– 68 128 110 874 1369 ND 12.4 (2.4–2.8)
2008–2011 HIVþ 13 901 32 153 1752 ND 32.3
HIV unknownb 222 641 758 564 14 168 ND 14.3
Manicaland, ZIM 21.9 All 67 225 319 384 3908 16.8 12.3 7.2 6.5
2000–2010 HIV– 28 330 99 621 579 4.7 (10.1–15.1) 4.3 (5.0–8.6)
2000–2010 HIVþ 6604 29 861 1406 58.5 28.1
HIV unknownb 59 060 189 903 1923 16.8 5.7
Masaka, UGA 9.4 All 21 999 105 860 1412 16.4 8.5 10.7 2.6
2000–2011 HIV– 17 342 81 138 772 10.6 (7–10.2) 8.6 (1.9–3.6)
2000–2011 HIVþ 1873 7753 390 90.0 22.7
HIV unknownb 11 221 16 970 250 14.1 14.9
Rakai, UGA 12.5 All 67 909 296 723 3668 16.9 21.2 9.2 6.6
2000–2010 HIV 34 331 148 308 559 4.5 (18.2–24.6) 3.4 (5.0–8.8)
2000–2010 HIVþ 5538 20 493 1210 96.2 22.5
HIV unknownb 59 194 127 922 1899 18.5 13.8
uMkhanyakude, RSA 35.4 All 88 230 467 619 9560 22.7 9.5 16.4 2.4
2001–2011 HIV 26 294 76 450 791 7.4 (4.4–20.6) 15.1 (2.1–2.7)
2004–2011 HIVþ 12 314 37 565 1711 69.9 36.0
HIV unknownb 87 791 353 603 7058 22.7 11.5
Total 18.5 All 550 477 2407,275 39 114 19.4 11.6 12.9 3.3
HIV 209 773 645 704 4997 6.7 (10.7–12.7) 9.5 (3.1–3.5)
HIVþ 43 498 137 894 6893 77.8 31.6
HIV unknownb 509 309 1623 677 27 224 21.0 12.2
CI, confidence interval; KEN, Kenya; MAW, Malawi; ND, no data; RR, rate ratio; RSA, South Africa; TAZ, Tanzania; UGA, Uganda; ZIM, Zimbabwe.
aAverage HIV prevalence¼HIVþ person-years/(HIVþ person-years þ HIV person-years). These prevalence estimates are relatively high because we include HIV
status information from medical facilities and treatment clinics, which increases the fraction of known HIV positives in our dataset.
bHIV unknown includes all the persons-years of exposure before the start of the HIV surveillance in the study site, and individual time prior to first HIV test.
study areas, and the nature of the terminating events of
residence episodes (administrative censoring, death, or
migration). HIV status information comes from com-
munity-based serological surveys, supplemented by self-
reports, proxy reports in post-mortem interviews, and
from record-linkage with health facilities used by
residents. The latter is also an important source for
retrieving data on the uptake of treatment. A few of the
ALPHA Network members have established reliable
record linkage between the demographic surveillance and
medical facility data with unique identifiers common to
individuals in clinic and community records (e.g.,
Karonga, Masaka, and uMkhanyakude), whereas others
(e.g., Kisumu) have piloted probabilistic record linkage.
To allocate person-time to HIV status and treatment
categories, we adopted a set of rules for censoring HIV
status and service use information. Individuals with a
report of an HIV-negative followed by an HIV-positive
test are assumed to have seroconverted at the midpoint
between the last negative and first positive test dates, and
allocate HIV-positive and HIV-negative exposure time
accordingly. Persons who are HIV positive at the time of
their first HIV test have all their observed exposure time
following the test classified as HIV positive. To calculate
mortality of HIV-negative individuals who remain
uninfected throughout the study, we classify all their
exposure time between tests as HIV negative. Following
their last negative test, they are classified as HIV negative
for a period of time corresponding to the 95% probability
of their age group remaining uninfected given the site and
sex-specific HIV incidence rates. Following that cut-off
point, their HIV status is considered unknown. Time
lived by individuals prior to the first recorded HIV test is
also classified as HIV status unknown. We classify
individuals as having received ART from the date on
which they were first recorded as receiving treatment. No
attempt is made to account for treatment adherence,
interruption, or cessation.
Statistical methods
We first present trends in the all-cause mortality rates of
adults aged 15–64 by sex, HIV status, and treatment
status. This is followed by parametric survival analysis of
the mortality hazards in HIV positives, whereby
individual age (radix at exact age 15) serves as a measure
of time. Among several possible distributions of the
outcome, the Weibull model, which describes mortality
patterns that increase steadily with age, was chosen on the
basis of Akaike’s Information Criterion, a statistic that
values both model fit and efficiency. Hazard ratio
estimates from the Weibull models are not qualitatively
different from semiparametric survival analysis, which
supports our choice for the Weibull distribution. Under
the proportional hazards specification of the Weibull
model and given a set of covariates, Xj, the age-specific
mortality hazard is given by:
hðagetjXj ¼ ptp1expðb0 þ XjbXÞ
where p represents the change in mortality by age. In
this application, we expect p> 1, which implies that the
hazard is monotone increasing with age.
As covariates, we consider calendar year, sex, and the
interaction between both. To investigate changes in the
mortality of HIV positives following the introduction of
ART, we fit separate models for the pre-ART and post-
ART period, whereby the coefficients for calendar year
quantify the impact of ARTas the average annual change
in the mortality hazard of HIV-positive adults. In the
post-ART period, we also allow the mortality rates for
HIV-positive men and women to differ by their treatment
status. The representation of calendar time is made using
two dichotomous variables: one that captures the period
in which treatment started to become locally available,
and one for subsequent years. This distinction is made
because the first year(s) of treatment rollout may feature
uncharacteristically high-mortality rates as a backlog of
patients with severe immunosuppression are quickly
ushered onto treatment. The case of Kisumu is special
because ART was introduced in 2007, but service
provision was severely affected by the violence that started
after the presidential elections of 27 December and lasted
until a truce was signed on 28 February 2008 [28].
Kisumu was one of the areas heavily implicated in the
protests against the ruling government and some excess
mortality may be associated with the protest itself.
Given declining incidence trends observed in some
surveys, and expected increases in longevity because of
treatment, there is a general lengthening of the duration
postinfection among PLHIV in the post-ART period.
However, the known seroconverters for whom duration
post infection can be measured constitute less than 12% of
PLHIV in the pooled dataset, so it is not practical to
introduce duration postinfection as another metric of
exposure.
Results
The pooled dataset contains 550477 individuals between
exact ages 15 and 65 (43498 with a known HIV positive
status), who jointly contribute 2.4 million person-years of
follow up time, and 39114 deaths (6893 to PLHIV). A
site-specific breakdown of these statistics is given in
Table 1. This table also contains crude mortality rates and
the rate ratios for HIV-positive over HIV-negative
mortality for the period 2000–2003, when ART was
not yet available in any of the sites, and for the period
2009–2011, when ARTwas locally available in all of the
study sites. These provide an indication of the mortality
reductions that have taken place since the rollout of ART.
In the early 2000s, the HIVþ/HIVmortality rate ratios
varied between 8.4 [Kisesa, 95% confidence interval (CI):
6.7–10.7] and 21.2 (Rakai, 95% CI: 18.2–24.6).
S536 AIDS 2014, Vol 28 (Suppl 4)
Between 2009 and 2011, these rate ratios ranged from 2.4
(uMkhanyakude, 95% CI: 2.1–2.7) to 6.6 (Rakai, 95%
CI: 5.0–8.8).
Figures 2 and 3 provide detailed descriptions of trends in
mortality rates by HIV status and treatment status. The
background shading in these illustration marks the years
that ART was locally introduced (between 2004 and
2007, depending on the site), and the years wherein the
rollout had been completed (between 2005 and 2009). In
an online appendix, we present mortality estimates by
study site, sex, HIV status, and selected calendar years in
Mortality trends in the antiretroviral therapy era in Africa Reniers et al. S537
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Fig. 2. All-cause death rates, and 95% confidence intervals, by study site, HIV status and sex (ages 15–64).
table format (Table A.1, http://links.lww.com/QAD/
A591), and also compare overall mortality with the
mortality for men and women whose HIV status has not
been measured in the study (Figure A.1, http://
links.lww.com/QAD/A591). The latter demonstrates
that mortality trends of men and women with an
unknown HIV status closely match overall mortality
trends, which suggest that there is no strong selection bias
in HIV status information in our datasets. uMkhanyakude
is the only site where the mortality rates of men and
women with unknown HIV status are consistently
different for a prolonged period of time. In this case,
they are lower than the overall mortality rate suggesting
that HIV-negative individuals are more likely to have an
HIV status that is unknown to the study.
The mortality rates of HIV-positive men and women
before the availability of treatment often exceeded 100
per thousand, without a clear upwards or downwards
trend (Fig. 2). Modest mortality declines in the last year
before the local introduction of ART are perhaps an
exception. The latter is most clearly visible in the
S538 AIDS 2014, Vol 28 (Suppl 4)
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Fig. 3. All-cause death rates and 95% confidence intervals among PLHIV, by study site and treatment status (ages 15–64, both
sexes). In a few instance, the estimates and confidence intervals have been truncated or modified to maintain the readability of the
plots. This affects the following estimates: Kisumu, 2008, had ART: 528 (95% confidence interval (CI): 374–747); Masaka, 2004,
had ART: 204 (95% CI: 106–392); and uMkhanyakude, 2005, had ART: 139 (95% CI: 77–251). Insufficient treatment uptake data
in Kisesa and Manicaland to conduct this analysis.
illustration for Masaka. Mortality declines are much more
pronounced in the period that ARTwas being rolled out
to health facilities located in the study sites. Compared
with the pre-ART years, total reductions in adult
mortality exceed 58% in all study sites. The mortality
rate for HIV-positive women in Masaka declined from
104.7 (95% CI: 71.3–153.8) in the year 2000 to 16.7
(95% CI: 8.4–33.4) in 2011, or, a total decline of 84%
(Table A.1, http://links.lww.com/QAD/A591).
In 2011, all-cause death rates among HIV-positive
women ranged from 11.7 (Karonga, 95% CI: 6.1–
22.5) to 22.7 per thousand (uMkhanyakude, 95% CI:
19.1–27.1); the ones for men varied between 13.3
(Masaka, 95%–CI: 5.0–35.3) and 51.7 per thousand
(Kisesa, 95%-CI: 25.8–103.3).
Rapid falls in the mortality of HIV positives have
contributed to a decline in overall adult mortality rates.
In 2003, these still ranged between 8.2 (Kisesa, 95% CI:
6.2–10.7) and 20.5 (Kisumu, 95% CI: 19.1–22.0) per
thousand for women, and between 10.1 (Kisesa, 95% CI:
7.9–13.0) and 23.5 (uMkhanyakude, 95% CI: 21.1–
26.1) per thousand for men. By 2011, adult female
mortality rates ranged between 2.9 (Kisesa, 95% CI: 1.9–
4.5) and 9.9 (uMkhanyakude, 95% CI: 8.7–11.3) per
thousand. Male, adult death rates are now as low as 4.6 per
thousand in Masaka (95% CI: 2.9–7.2). The highest
observed value for men is 12.5 per thousand (uMkha-
nyakude, 95% CI: 10.9–14.4). The results presented in
Fig. 2 and Table A.1, http://links.lww.com/QAD/A591
are not suggestive of clear trends in the mortality rates of
HIV-negative individuals.
Figure 3 shows that there has been a decline in the
mortality of HIV positives who ever started treatment,
but also among PLHIV without a record of treatment
initiation. The mortality rates of men and women who
started ART is often very high during the first year(s) that
ART became available in the study sites. In subsequent
years, both the level and trend in mortality rates are
comparable in the two treatment status categories.
uMkhanyakude is the only study site with consistent
and relatively large differences in the mortality of HIV
positives with and without ART.
The assessment of trends in the mortality rates of HIV-
positive men and women is extended in Table 2, which
contains site-specific estimates of the mortality hazard
ratios from parametric survival models. The auxiliary
parameter of the Weibull model ( p) captures the rising
mortality risk with age. More pertinent for the current
discussion is the change in age-adjusted mortality rates
over time. Separate models fitted for the pre-ART and
post-ART period indicate that age-adjusted mortality
rates among PLHIVonly started declining after the local
introduction of ART (none of the hazard ratios for
calendar year in the pre-ART period were significantly
smaller than 1). The coefficients for the post-ART period
are indicative of an average annual decline in the mortality
hazard ranging from 13% in Kisesa (hazard ratio 0.87, 95%
CI: 0.83–92) to 38% in Kisumu (hazard ratio 0.62, 95%
CI: 0.59–0.65).
Pre-ART mortality rates among HIV positive men and
women are comparable, but gender differences became
more pronounced following the introduction of treat-
ment. Gender differences are statistically significant in five
out of seven study sites in the post-ART era (Karonga,
Kisesa, Kisumu, Rakai, and uMkhanyakude), and the
female advantage increases over time in two of the study
sites (Rakai and uMkhanyakude) as shown by the
interaction between sex and calendar year.
Table 2 also formalizes the comparison of adult mor-
tality rates among HIV positives who initiated ART
and HIV positives without a record of treatment. The
mortality levels and trends in both groups are generally
comparable, but the early years of local ARTavailability are
an important exception. In three of the four study siteswith
available data, the mortality hazard is significantly elevated
among patients who accessed treatment in the early rollout
stages. The highest ratio of mortality hazards is observed in
Kisumu (hazard ratio 6.23, 95% CI: 4.68–8.29). In later
years, the mortality hazard in patients who ever started
treatment is sometimes higher (e.g., uMkhanyakude),
sometimes lower (e.g., Rakai), and often not significantly
different (e.g., Kisumu and Masaka).
Discussion
Our results demonstrate the large impact of AIDS
treatment programmes on adult mortality in eastern and
southern Africa. In most study sites, the mortality of HIV
positives had been relatively stable with some signs of a
mortality decline just prior to the local introduction of
ART. This decline could result from increased efforts to
treat opportunistic infections, or, from patients receiving
treatment at medical facilities outside of the actual study
sites. However, the local rollout of ART had a muchmore
sizable and sustained effect. All study sites have witnessed
average annual reductions in the mortality hazards of
HIV-positive adults in excess of 10% ever since, and total
mortality declines following the expansion of ART vary
between 58 and 84%. The largest mortality reduction has
been recorded in Kisumu, but its mortality rates for 2008,
the year following the introduction of ART, were
exceptionally high and probably associated with the
postelectoral violence and interruption of medical
services. Despite the strong mortality reductions among
PLHIV in all study sites, the morality rates of HIV-
positive adults are still between 2.4 and 6.6 times higher
than those of HIV negatives (both sexes combined),
which underlines that there is still much room for
improving ART coverage and impact.
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Gender differences in the mortality rates of PLHIV only
started to appear as treatment was being rolled out. The
estimated mortality hazards for men are now significantly
higher in five of the seven study sites and have been
increasing over time in two of those five sites. Our
results thus corroborate earlier findings that women have
benefitted more from the expansion of treatment
programmes, either through a higher uptake of ART,
better treatment outcomes, or both. Despite the more
successful engagement of women in HIV care and
treatment programmes, it is premature to conclude that
this has created a new gender disparity whereby men are
most disadvantaged. First, it is unclear whether the larger
mortality reductions among HIV-positive women have
reversed the burden of HIV in terms of the life years lost
to HIV. Second, a lower uptake of treatment among
men could imply that their female partners will not be as
well protected against infection as the male partners of
HIV-positive women. In other words, gender disparities
in the utilization of HIV services may sustain previously
observed gender disparities in the number of new
infections, which have generally been higher in women.
In most of the study sites, the mortality trend of PLHIV
who started ART is comparable with the trend of those
not (yet) on treatment. This is a good indication that
programmes are increasingly successful in ensuring timely
transitions along the cascade of HIV care and treatment: as
PLHIV initiate treatment earlier, treatment failures are
reduced, but importantly, pretreatment mortality also
declines as those with advanced disease are selected onto
treatment, leaving an increasingly healthy not-on-ART
population. Other factors, such as changes in treatment
eligibility criteria and the availability of better drugs, will
complement or enhance this pattern. Despite broad
similarities in the mortality trends of PLHIV who have
and have not initiated treatment, there are a couple of
notable differences. First, the mortality of PLHIV on
treatment during the rollout phase was generally much
higher, probably because PLHIV who began treatment as
soon as it became locally available had advanced disease
progression at the time of initiation. Second, there are a
couple of sites, uMkhanyakude and to a lesser extent
Karonga, where the mortality of PLHIV who started
ART continues to be higher than among those for whom
we do not have a record of treatment initiation. This may
indicate either that linkage to care is more efficient in
these settings (lowering pretreatment mortality), or that
mortality following treatment initiation is higher for
other reasons.
The population perspective offered by the ALPHA
Network data is an invaluable attribute for studying the
impact of treatment scale-up in the region, but the close
monitoring of HIV status, services uptake and vital events
is only practically feasible in relatively small populations,
and these come with their own limitations. An often-
cited drawback of demographic surveillance sites is their
lack of generalizability, but the consistency of findings
across study sites strengthens our belief that results are not
driven by the particularities of each study site (including
variations in data collection protocols). Small populations
are typically also affected by high levels of mobility in and
out of the study sites, and previous work has demonstrated
its association with HIV status [29–31]. How these
relationships may have changed following the expansion
of treatment programmes is not clear, and we reserve this
subject for future inquiry.
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